Jose Isidro Belda Sanchis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Isidro Belda Sanchis has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Fea
Eye Clinic, University of Turin, Turin
2 shared publications - Julian Garcia-Feijoo
Instituto de Investigaciones Ramon Castroviejo, Hospital Clinico, Universidad Complutense, Madrid, Spain
2 shared publications Anselm Juenemann
Universitätsaugenklinik, Erlangen, Germany
1 shared publicationAnselm Jünemann
Department of Ophthalmology, University Hospital Erlangen, Erlangen, Germany
1 shared publicationBlas Mompean
1 shared publicationCarmen Rey
1 shared publication
Latest Publications
- 22 June 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (7) , 1243-1249
The Thickness of the Retinal Nerve Fiber Layer (RNFL) as a Biomarker in Uveitis
To study the changes of the retinal nerve fiber layer (RNFL) thickness during and following uveitis flares. This was a retrospective study of patients with uveitis diagnosed in the ophthalmology service of Torrevieja hospital. We analyzed RNFL thickness during and after the acute episode. We included 29 patients. Most patients (55.2%) had anterior uveitis; followed by posterior, intermediate and panuveitis. Mean RNFL thickness was significantly higher during the flare (132.17±35.54μm vs 107.66±17.10μm). RNFL thickness had no difference between groups with or without macular edema. The RNFL thickens during flares in most patients with uveitis. It can be measured by optical coherence tomography in a non-invasive way, representing an objective marker of inflammation. This can favor earlier detection of flares, resolution, and recurrence of uveitis. More studies are needed to determine the evolution of RNFL over time and in different types of uveitis.
- 22 June 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (7) , 1243-1249
The Thickness of the Retinal Nerve Fiber Layer (RNFL) as a Biomarker in Uveitis
To study the changes of the retinal nerve fiber layer (RNFL) thickness during and following uveitis flares. This was a retrospective study of patients with uveitis diagnosed in the ophthalmology service of Torrevieja hospital. We analyzed RNFL thickness during and after the acute episode. We included 29 patients. Most patients (55.2%) had anterior uveitis; followed by posterior, intermediate and panuveitis. Mean RNFL thickness was significantly higher during the flare (132.17±35.54μm vs 107.66±17.10μm). RNFL thickness had no difference between groups with or without macular edema. The RNFL thickens during flares in most patients with uveitis. It can be measured by optical coherence tomography in a non-invasive way, representing an objective marker of inflammation. This can favor earlier detection of flares, resolution, and recurrence of uveitis. More studies are needed to determine the evolution of RNFL over time and in different types of uveitis.
- Open Access
- 1 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Long‐Term Clinically Significant Posterior Capsular Opacification Development Pattern in Eyes Implanted with an Aspheric Monofocal Intraocular Lens with a Square Optic Edge
Purpose . To analyse the posterior capsular opacification (PCO) development pattern in the long term in eyes implanted with a monofocal intraocular lens (IOL) with a square edge all around the optic. Methods . Longitudinal retrospective study is data analyzed from a total of 7059 eyes from 4764 patients (mean age: 75.8 years) undergoing cataract surgery with implantation of an aspheric monofocal IOL (Bi‐Flex HL 677AB/677P, Medicontur, Budapest, Hungary). These data were retrospectively collected using the electronic medical record of the hospitals involved. Nd : YAG capsulotomy rates were calculated per year during a follow‐up of more than 10 years. The Kaplan–Meier analysis was used to establish the transparent capsule survival rate. Results . The Nd : YAG capsulotomy rate increased from 1.1% at 1 year postoperatively to 17.2% at 5 years after surgery. No significant differences were found between eyes with and without capsulotomy in terms of age ( p = 0.202), gender ( p = 0.061), type of anaesthesia used ( p = 0.128), and presence of conditions such as hard cataract ( p = 0.111) or pseudoexfoliation ( p = 0.137). IOL power was significantly lower in those eyes of patients requiring Nd : YAG capsulotomy during the follow‐up ( p < 0.001). Significantly more eyes implanted with the preloaded model of the IOL required capsulotomy ( p < 0.001). Mean survival time and rate were 9.38 years and 85.9%, respectively. Conclusions . Most eyes undergoing cataract with implantation of the Bi‐Flex IOL do not develop a clinically significant PCO requiring Nd : YAG capsulotomy in the long term. IOL material and design may be the main factors accounting for this finding.
- 1 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Open AccessLong‐Term Clinically Significant Posterior Capsular Opacification Development Pattern in Eyes Implanted with an Aspheric Monofocal Intraocular Lens with a Square Optic Edge
Purpose . To analyse the posterior capsular opacification (PCO) development pattern in the long term in eyes implanted with a monofocal intraocular lens (IOL) with a square edge all around the optic. Methods . Longitudinal retrospective study is data analyzed from a total of 7059 eyes from 4764 patients (mean age: 75.8 years) undergoing cataract surgery with implantation of an aspheric monofocal IOL (Bi‐Flex HL 677AB/677P, Medicontur, Budapest, Hungary). These data were retrospectively collected using the electronic medical record of the hospitals involved. Nd : YAG capsulotomy rates were calculated per year during a follow‐up of more than 10 years. The Kaplan–Meier analysis was used to establish the transparent capsule survival rate. Results . The Nd : YAG capsulotomy rate increased from 1.1% at 1 year postoperatively to 17.2% at 5 years after surgery. No significant differences were found between eyes with and without capsulotomy in terms of age ( p = 0.202), gender ( p = 0.061), type of anaesthesia used ( p = 0.128), and presence of conditions such as hard cataract ( p = 0.111) or pseudoexfoliation ( p = 0.137). IOL power was significantly lower in those eyes of patients requiring Nd : YAG capsulotomy during the follow‐up ( p < 0.001). Significantly more eyes implanted with the preloaded model of the IOL required capsulotomy ( p < 0.001). Mean survival time and rate were 9.38 years and 85.9%, respectively. Conclusions . Most eyes undergoing cataract with implantation of the Bi‐Flex IOL do not develop a clinically significant PCO requiring Nd : YAG capsulotomy in the long term. IOL material and design may be the main factors accounting for this finding.
- 1 May 2018
- Published by SLACK, Inc. in Journal of Pediatric Ophthalmology & Strabismus
- Vol. 55 (3) , 171-177
Optical Coherence Tomography in Children With Microtropia
Purpose: To assess whether optical coherence tomography (OCT) could be useful for detecting and documenting fixation in patients with microtropia. Methods: Retinal fixation observation was performed using spectral-domain OCT on amblyopic children with microtropia. The position between the retinal fixation point and the anatomical fovea was measured, in microns, using the system software tools. Only patients with a high level of cooperation, OCT scan quality signal of 7 or better, and visual acuity of 0.70 logarithm of the minimum angle of resolution (logMAR) or worse in the amblyopic eye were included. Results: A total of 25 patients were included: 15 with microtropia (study group) and 10 without tropia and with foveal fixation and stereopsis (control group). In the study group, microtropia was previously diagnosed in 67% of cases through the cover test, and was predominantly in the left eye (73%). The average visual acuity of the sound eye was 0.03 decimal and 0.18 logMAR in the amblyopic eye. The microtropia was 3.73 ± 3.34 prism diopters and eccentric fixation (387 ± 199 µm) with OCT was observed in all cases except one. Eccentricity was predominantly in the superonasal quadrant (57%). Both eyes in the control group and the contralateral eyes of the study group showed foveal fixation. Conclusions: OCT can play an important role in the diagnosis and measurement of eccentric fixation in eyes with microtropia, providing high sensitivity. [ J Pediatr Ophthalmol Strabismus . 2018;55(3):171–177.]
- 1 May 2018
- Published by SLACK, Inc. in Journal of Pediatric Ophthalmology & Strabismus
- Vol. 55 (3) , 171-177
Optical Coherence Tomography in Children With Microtropia
Purpose: To assess whether optical coherence tomography (OCT) could be useful for detecting and documenting fixation in patients with microtropia. Methods: Retinal fixation observation was performed using spectral-domain OCT on amblyopic children with microtropia. The position between the retinal fixation point and the anatomical fovea was measured, in microns, using the system software tools. Only patients with a high level of cooperation, OCT scan quality signal of 7 or better, and visual acuity of 0.70 logarithm of the minimum angle of resolution (logMAR) or worse in the amblyopic eye were included. Results: A total of 25 patients were included: 15 with microtropia (study group) and 10 without tropia and with foveal fixation and stereopsis (control group). In the study group, microtropia was previously diagnosed in 67% of cases through the cover test, and was predominantly in the left eye (73%). The average visual acuity of the sound eye was 0.03 decimal and 0.18 logMAR in the amblyopic eye. The microtropia was 3.73 ± 3.34 prism diopters and eccentric fixation (387 ± 199 µm) with OCT was observed in all cases except one. Eccentricity was predominantly in the superonasal quadrant (57%). Both eyes in the control group and the contralateral eyes of the study group showed foveal fixation. Conclusions: OCT can play an important role in the diagnosis and measurement of eccentric fixation in eyes with microtropia, providing high sensitivity. [ J Pediatr Ophthalmol Strabismus . 2018;55(3):171–177.]
- 1 June 2015
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 90 (6) , 274-284
Manejo farmacológico perioperatorio en pacientes con glaucoma
- 1 June 2015
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 90 (6) , 274-284
Manejo farmacológico perioperatorio en pacientes con glaucoma
- Open Access
- 1 May 2014
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 8, 875-882
Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma
Purpose: The purpose of this study was to compare outcomes of subjects with open-angle glaucoma (OAG) not controlled on one medication who underwent either implantation of two iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed combination of latanoprost/timolol. Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98 to receive medical therapy. Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of ≥20% versus baseline unmedicated IOP, and 91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction ≥20% versus baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent inject group was statistically significant (P=0.02) at the ≥50% level of IOP reduction. An IOP ≤18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, cup-to-disc ratio, and adverse events. Conclusion: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment with full compliance to implant therapy as well as having a highly favorable safety profile.
- 1 May 2014
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 8, 875-882
Open AccessProspective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma
Purpose: The purpose of this study was to compare outcomes of subjects with open-angle glaucoma (OAG) not controlled on one medication who underwent either implantation of two iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed combination of latanoprost/timolol. Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98 to receive medical therapy. Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of ≥20% versus baseline unmedicated IOP, and 91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction ≥20% versus baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent inject group was statistically significant (P=0.02) at the ≥50% level of IOP reduction. An IOP ≤18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, cup-to-disc ratio, and adverse events. Conclusion: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment with full compliance to implant therapy as well as having a highly favorable safety profile.
- Open Access
- 23 January 2014
- Published by Springer Nature in Advances in Therapy
- Vol. 31 (2) , 189-201
Prospective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy Trial
Introduction Micro-invasive glaucoma surgical implantation of trabecular micro-bypass stents, previously shown to be safe and effective for open-angle glaucoma (OAG) subjects during cataract surgery, was considered for evaluation as a sole procedure. The aim of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy after ab interno implantation of two Glaukos Trabecular Micro-Bypass iStent inject second generation devices in subjects with OAG. This study was performed at sites in France, Germany, Italy, Republic of Armenia, and Spain. Methods In this pan-European, multi-center prospective, post-market, unmasked study, 99 patients with OAG on at least two topical ocular hypotensive medications who required additional IOP lowering to control glaucoma disease underwent implantation of two GTS400 stents in a stand-alone procedure. Patients were qualified if they presented with preoperative mean IOP between 22 and 38 mmHg after medication washout. Postoperatively, subjects were assessed at Day 1, Months 1, 3, 6, 7, 9, and 12. IOP, medication use and safety were assessed at each visit. Results Sixty-six percent of subjects achieved IOP ≤18 mmHg at 12 months without medication, and 81% of subjects achieved Month 12 IOP ≤ 18 mmHg with either a single medication or no medication. Mean baseline washout IOP values decreased by 10.2 mmHg or 39.7% from 26.3 (SD 3.5) mmHg to 15.7 (SD 3.7) mmHg at Month 12. Mean IOP at 12 months was 14.7 (SD 3.1) mmHg in subjects not using ocular hypotensive medications. Reduction from preoperative medication burden was achieved in 86.9% of patients, including 15.2% with reduction of one medication and 71.7% with reduction of two or more medications. Postoperative complications occurred at a low rate and resolved without persistent effects. Conclusion In this series, implantation of two trabecular micro-bypass second generation stents in subjects with OAG resulted in IOP and medication reduction and favorable safety outcomes.
- 23 January 2014
- Published by Springer Nature in Advances in Therapy
- Vol. 31 (2) , 189-201
Open AccessProspective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy Trial
Introduction Micro-invasive glaucoma surgical implantation of trabecular micro-bypass stents, previously shown to be safe and effective for open-angle glaucoma (OAG) subjects during cataract surgery, was considered for evaluation as a sole procedure. The aim of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy after ab interno implantation of two Glaukos Trabecular Micro-Bypass iStent inject second generation devices in subjects with OAG. This study was performed at sites in France, Germany, Italy, Republic of Armenia, and Spain. Methods In this pan-European, multi-center prospective, post-market, unmasked study, 99 patients with OAG on at least two topical ocular hypotensive medications who required additional IOP lowering to control glaucoma disease underwent implantation of two GTS400 stents in a stand-alone procedure. Patients were qualified if they presented with preoperative mean IOP between 22 and 38 mmHg after medication washout. Postoperatively, subjects were assessed at Day 1, Months 1, 3, 6, 7, 9, and 12. IOP, medication use and safety were assessed at each visit. Results Sixty-six percent of subjects achieved IOP ≤18 mmHg at 12 months without medication, and 81% of subjects achieved Month 12 IOP ≤ 18 mmHg with either a single medication or no medication. Mean baseline washout IOP values decreased by 10.2 mmHg or 39.7% from 26.3 (SD 3.5) mmHg to 15.7 (SD 3.7) mmHg at Month 12. Mean IOP at 12 months was 14.7 (SD 3.1) mmHg in subjects not using ocular hypotensive medications. Reduction from preoperative medication burden was achieved in 86.9% of patients, including 15.2% with reduction of one medication and 71.7% with reduction of two or more medications. Postoperative complications occurred at a low rate and resolved without persistent effects. Conclusion In this series, implantation of two trabecular micro-bypass second generation stents in subjects with OAG resulted in IOP and medication reduction and favorable safety outcomes.